The Metabolic Institute of America

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

Amputations have increased 30% among diabetic patients since the pandemic began.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

Dr. Kausik Ray presents new data on inclisiran and bempedoic acid as cholesterol lowering medications.

The TMIOA Medical Director highlights the best sessions, new topics, and growing discussion around the 18th annual congress.